Re: Farmas USA
OMED
Falla fase II y abre con -44%
phase 2 Demcizumab pancreatic trial misses primary endpoint
Based on PFS, OS and ORR adding demcizumab to Abraxane plus gemcitabine was harmful. TX arm arms pretty much worse in all categories
Bayer terminated its option to license Wnt pathway inhibitors Vantictumab or Ipafricept
«Después de nada, o después de todo/ supe que todo no era más que nada.»